The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update.
 
Aung Naing
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Baxter (I); EMD Serono; Healios; Incyte; Karyopharm Therapeutics; MedImmune; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Jeffrey R. Infante
Research Funding - Celldex (Inst)
 
J. Randolph Hecht
No Relationships to Disclose
 
Kyriakos P. Papadopoulos
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Novartis (Inst); Onyx (Inst); Regeneron (Inst); Sanofi (Inst)
 
Deborah Jean Lee Wong
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca/MedImmune; BioMed Valley Discoveries; Kura Oncology; Merck Serono; Merck Sharp & Dohme
 
Karen A. Autio
No Relationships to Disclose
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; Celgene; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; GlaxoSmithKline; Hutchison MediPharma; Incyte; Kolltan Pharmaceuticals; MedImmune; Millennium; Novartis; Regeneron; Strategia Therapeutics; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - EMD Serono; Millennium; Sarah Cannon Research Institute
 
Manish R. Patel
No Relationships to Disclose
 
Patrick Alexander Ott
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Neon Therapeutics
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - AVEO (Inst); Bayer (Inst); Corvus Pharmaceuticals (Inst); Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Plexxikon (Inst); Symphony Evolution (Inst); Tesaro (Inst)
 
Johanna C. Bendell
Research Funding - Apexigen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst)
 
Peter Van Vlasselaer
Employment - ARMO BioSciences
Leadership - ARMO BioSciences
Stock and Other Ownership Interests - ARMO BioSciences
 
David S. Hong
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Exelixis; GlaxoSmithKline; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; GlaxoSmithKline; Nektar; Novartis
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis; GlaxoSmithKline; Nektar; Novartis; Pfizer
 
Martin Oft
Employment - ARMO BioSciences